GRI Report

Overview

The report describes the company's role in enabling biotechnology-based drugs, vaccines and biopharmaceutical medicines, while refining its climate strategy around emissions intensity. It sets an average annual 20% reduction target for Scope 1 and 2 emissions intensity through 2030. For 2021, it reports 36,914 t CO2eq of total GHG emissions, 136,424 MWh of total energy consumption and a workforce of 10,409 employees.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2021
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level

Materiality

Assessment
Basis

Assurance

Provider
Level
Standard
Scope
Statement included
Metrics assured

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services